26441-05-4 Usage
Description
15-keto Prostaglandin E2 (15-keto PGE2) is a metabolite of PGE2 (Item Nos. 14010) formed by 15-hydroxy prostaglandin dehydrogenase (15-PGDH). Unlike PGE2, 15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 2.6 and 15 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = 1.8 and >33 μM, respectively). However, it does bind to EP2 and EP4 in HEK cells expressing these receptors (IC50s = 0.117 and 2.82 μM, respectively), as well as induces cAMP formation (EC50s = 0.137 and 0.426 μM, respectively) and the transcriptional activity of β-catenin/TCF in the same cells. 15-keto PGE2 inhibits CD3-CD28-MHC-I-induced proliferation of isolated human CD4+ T cells in a concentration-dependent manner. It also reduces mortality in a mouse model of LPS-induced sepsis when administered at a dose of 15 mg/kg.15-keto PGE2 MaxSpec? standard is a quantitative grade standard of 15-keto PGE2 that has been prepared specifically for mass spectrometry or any application where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This 15-keto PGE2 MaxSpec? standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Uses
Different sources of media describe the Uses of 26441-05-4 differently. You can refer to the following data:
1. 15-keto Prostaglandin E2 (15-keto PGE2) is a metabolite of PGE2 formed by 15-hydroxy PGDH. In vivo, 15-keto PGE2 is essentially inactive. It has an attenuated affinity for the EP4 and EP2 receptors compared to PGE2 (Ki = 2,600-15,000 nM for the inhibition of PGE2 binding compared to a Kd = 1 nM for PGE2).[Cayman Chemical]
2. 15-Keto Prostaglandin E2 is a lipid compound derived from arachidonic acid by the action of cyclooxygenases. Prostaglandins act locally as messenger molecules in a variety of physiological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 26441-05-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,4,4 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 26441-05:
(7*2)+(6*6)+(5*4)+(4*4)+(3*1)+(2*0)+(1*5)=94
94 % 10 = 4
So 26441-05-4 is a valid CAS Registry Number.
InChI:InChI=1/C20H30O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,16-17,19,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t16-,17-,19-/m1/s1
26441-05-4Relevant articles and documents
Role of glutamine 148 of human 15-hydroxyprostaglandin dehydrogenase in catalytic oxidation of prostaglandin E2
Cho, Hoon,Huang, Lingyu,Hamza, Adel,Gao, Daquan,Zhan, Chang-Guo,Tai, Hsin-Hsiung
, p. 6486 - 6491 (2006)
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a member of the short-chain dehydrogenase/reductase (SDR) family, catalyzes the first step in the catabolic pathways of prostaglandins and lipoxins. This enzyme oxidizes the C-15 hydroxyl group of prostaglandins and lipoxins to produce 15-keto metabolites which exhibit greatly reduced biological activities. A three-dimensional (3D) structure of 15-PGDH based on the crystal structures of the levodione reductase and tropinone reductase-II was generated and used for docking study with NAD+ coenzyme and PGE2 substrate. Three well-conserved residues among SDR family which correspond to Ser-138, Tyr-151, and Lys-155 of 15-PGDH have been shown to participate in the catalytic reaction. Based on the molecular interactions observed from 3D structure of 15-PGDH, we further propose that Gln-148 in 15-PGDH is important in properly positioning the 15-hydroxyl group of PGE2 by hydrogen bonding with the side-chain oxygen atom of Gln-148. This residue is found to be less conserved and replaceable by glutamyl, histidinyl, and asparaginyl residues in SDR family. Accordingly, site-directed mutagenesis of Gln-148 of 15-PGDH to alanine, glutamic acid, histidine, and asparagine (Q148A, Q148E, Q148H, and Q148N) was carried out. The activity of mutant Q148A was not detectable, whereas those of mutants Q148E, Q148H, and Q148N were comparable to or higher than the wild type. This indicates that the side-chain oxygen or nitrogen atom at position 148 of 15-PGDH plays an important role in anchoring C-15 hydroxyl group of PGE2 through hydrogen bonding for catalytic reaction.
METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH)
-
Paragraph 0029; 0036; 0055; 0203, (2020/12/30)
The present disclosure provides compositions and methods based on the identification of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a therapeutic target in aging, dystrophic muscle to improve muscle atrophy, increase muscle mass, function and strength. Further provided herein are compositions and methods for the rejuvenation of aged tissue. In particular, 15-PGDH inhibitors, such as SW033291, are used to elevate the levels of prostaglandin E2 (PGE2) in the muscle or tissue.
